Sunday, November 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· February 18, 2026

5 Financial Transaction Stocks to Watch Despite Elevated Expense Level

View original at finance.yahoo.com
5 Financial Transaction Stocks to Watch Despite Elevated Expense Level The Financial Transaction Services industry is likely to benefit from expanding global trade, rising international travel and growing demand for seamless cross-border payments and remittances…
Opening lines of the source · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Financial Transaction Services industry is likely to benefit from expanding global trade, rising international travel and growing demand for seamless cross-border payments and remittances

    80% confidence
  • The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one

    80% confidence
  • Visa carries a Zacks Rank #3 (Hold)

    80% confidence
  • In the past five years, the Financial Transaction Services industry traded as high as 36.92X, as low as 18.15X and at the median of 22.24X on a forward P/E basis

    80% confidence
  • Zacks Consensus Estimate for Visa's fiscal 2026 earnings is $12.84 per share, indicating an 11.9% rise from the year-ago figure

    80% confidence
  • The Zacks Financial Transaction Services industry currently carries a Zacks Industry Rank #135, placing it in the bottom 44% of 243 Zacks industries

    80% confidence
  • Fiserv's earnings beat estimates in three of the last four quarters and missed once

    80% confidence
  • Global Payments carries a Zacks Rank #2 (Buy)

    80% confidence
  • Fidelity National's earnings beat estimates in three of the last four quarters and matched once, with average surprise of 1.64%

    80% confidence
  • Mastercard's earnings beat estimates in each of the last four quarters, with an average surprise of 5.48%

    80% confidence
  • Visa's earnings beat estimates in each of the last four quarters, with an average surprise of 2.12%

    80% confidence
  • The Financial Transaction Services industry has declined 24.3% compared with the Business Services sector's decline of 24.4% over the past year

    80% confidence
  • The Financial Transaction Services industry is currently trading at a forward 12-month P/E of 18.15X, compared with the S&P 500's 22.51X and the sector's 18X

    80% confidence
  • Fidelity National carries a Zacks Rank #3 (Hold)

    80% confidence
  • With expectations for interest rate cuts in 2026, companies may increasingly use debt financing to fund acquisitions and accelerate growth

    80% confidence
  • Mastercard carries a Zacks Rank #3 (Hold)

    80% confidence
  • Zacks Consensus Estimate for Mastercard's 2026 earnings is $19.38 per share, indicating a 13.9% rise from the year-ago figure

    80% confidence
  • Zacks Consensus Estimate for Global Payments' 2026 earnings is $13.85 per share, indicating a 13.3% rise from the 2025 estimate

    80% confidence
  • Persistent inflation and tariff pressures may further strain consumer budgets in the financial transaction services space

    80% confidence
  • Zacks Consensus Estimate for Fiserv's 2026 earnings is $8.14 per share, with revenue consensus implying 3.4% improvement from year-ago

    80% confidence
  • Fiserv carries a Zacks Rank #3 (Hold)

    80% confidence
  • Zacks Consensus Estimate for Fidelity National's 2026 earnings is $6.27 per share, indicating an improvement of 8.7% from the 2025 estimate

    80% confidence
  • Global Payments' earnings beat estimates in three of the last four quarters and missed once, with an average surprise of 1.93%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Sources reconciled: no open conflicts right now.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com
5 Financial Transaction Stocks to Watch Despite Elevated Expense Level: Source | Via News | finance.via.news